Alec Stranahan
Stock Analyst at B of A Securities
(0.57)
# 4,158
Out of 5,149 analysts
33
Total ratings
34.62%
Success rate
-51.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $288 → $318 | $263.80 | +20.55% | 6 | Jan 22, 2026 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $4.91 | +42.57% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $12.02 | -0.17% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $14.10 | -92.91% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $9.49 | -26.24% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $27.22 | +54.30% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $10.03 | +149.25% | 5 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.76 | +525.00% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $5.17 | +16.05% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.04 | +635.29% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $100.49 | -45.27% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $28.88 | -79.22% | 2 | Dec 29, 2022 |
Krystal Biotech
Jan 22, 2026
Maintains: Buy
Price Target: $288 → $318
Current: $263.80
Upside: +20.55%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $4.91
Upside: +42.57%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $12.02
Upside: -0.17%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $14.10
Upside: -92.91%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $9.49
Upside: -26.24%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $27.22
Upside: +54.30%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $10.03
Upside: +149.25%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.76
Upside: +525.00%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $5.17
Upside: +16.05%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.04
Upside: +635.29%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $100.49
Upside: -45.27%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $28.88
Upside: -79.22%